InvestSMART

ResMed Inc. (ASX: RMD) - Announcements

- Current share price for RMD : $30.700

ASX company news and announcements for ResMed Inc. (RMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ResMed Inc. (RMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ResMed Inc. (RMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ResMed Inc. (RMD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18,236 Director Appointment/Resignation 4 Jul 2022 8:09AM $30.500 $30.700 risen by 0.66%
$18,236 Form 8-K 1 Jul 2022 10:06AM $30.690 $30.700 risen by 0.03%
$18,236 ResMed to Acquire MEDIFOX DAN 15 Jun 2022 11:25AM $29.320 $30.700 risen by 4.71%
$18,236 Statement of CDIs on issue - RMD 6 Jun 2022 9:09AM $29.070 $30.700 risen by 5.61%
$18,236 FORM SD 27 May 2022 8:22AM $27.960 $30.700 risen by 9.80%
$18,236 Update - Dividend/Distribution - RMD 13 May 2022 2:42PM $28.275 $30.700 risen by 8.58%
$18,236 Director Appointment/Resignation 12 May 2022 8:25AM $28.420 $30.700 risen by 8.02%
$18,236 Statement of CDIs on issue - RMD 5 May 2022 9:45AM $27.780 $30.700 risen by 10.51%
$18,236 FORM 10Q for Qtr ended March, 2022 2 May 2022 8:45AM $29.140 $30.700 risen by 5.35%
$18,236 Dividend/Distribution - RMD 29 Apr 2022 8:05AM $30.380 $30.700 risen by 1.05%
$18,236 ResMed Announces Results for the Third Quarter of FY2022 29 Apr 2022 8:04AM $30.380 $30.700 risen by 1.05%
$18,236 RMD to Report Third Quarter Fiscal 2022 Results 8 Apr 2022 8:54AM $32.810 $30.700 fallen by 6.43%
$18,236 Statement of CDIs on issue - RMD 5 Apr 2022 10:15AM $32.740 $30.700 fallen by 6.23%
$18,236 Statement of CDIs on issue - RMD 4 Mar 2022 3:56PM $33.860 $30.700 fallen by 9.33%
$18,236 Update - Dividend/Distribution - RMD 11 Feb 2022 2:54PM $34.070 $30.700 fallen by 9.89%
$18,236 Statement of CDIs on issue - RMD 4 Feb 2022 12:51PM $33.370 $30.700 fallen by 8%
$18,236 FORM 10Q for Qtr ended December, 2021 31 Jan 2022 9:36AM $31.250 $30.700 fallen by 1.76%
$18,236 Dividend/Distribution - RMD 28 Jan 2022 8:32AM $31.400 $30.700 fallen by 2.23%
$18,236 ResMed Announces Results for the Second Quarter of FY2022 28 Jan 2022 8:29AM $31.400 $30.700 fallen by 2.23%
$18,236 Statement of CDIs on issue - RMD 7 Jan 2022 1:58PM $33.920 $30.700 fallen by 9.49%
$18,236 RMD to Report Second Quarter Fiscal 2022 Results 7 Jan 2022 8:46AM $33.640 $30.700 fallen by 8.74%
$18,236 Statement of CDIs on issue - RMD 3 Dec 2021 1:43PM $35.850 $30.700 fallen by 14.37%
$18,236 FORM 8-K Annual Meeting Stockholders 22 Nov 2021 8:20AM $36.330 $30.700 fallen by 15.50%
$18,236 Update - Dividend/Distribution - RMD 12 Nov 2021 1:50PM $34.855 $30.700 fallen by 11.92%
$18,236 Statement of CDIs on issue - RMD 5 Nov 2021 10:09AM $35.870 $30.700 fallen by 14.41%

351 - 375 of 703 results

Page 15 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.